
-
Applied Therapeutics NasdaqGM:APLT Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Location: 545 Fifth Avenue, New York, NY, 10017, United States | Website: https://www.appliedtherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
37.29M
Cash
50.76M
Avg Qtr Burn
-23.51M
Short % of Float
13.39%
Insider Ownership
4.90%
Institutional Own.
85.75%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Govorestat (AT-007) Details Galactosemia, Rare diseases, Rare genetic disease | NDA Resubmission | |
Govorestat (AT-007) Details Sorbitol dehydrogenase deficiency | NDA Submission | |
Caficrestat (AT-001) Details Hemophilia, Genetic disorder, Diabetic cardiomyopathy | Phase 3 Update | |
Govorestat (AT-007) Details Phosphomannomutase 2 deficiency , Congenital disorder of glycosylation | Phase 2 Update | |
AT-003 Details Diabetic retinopathy | Phase 1 Update | |
AT-104 Details Leukemia, B-cell acute lymphoblastic leukemia, T-cell lymphoma | Failed Discontinued |